← Back to all trials
Completed
NCT04749368
Study to Investigate the Safety and Efficacy of BRII-835 and BRII-179 Combination Therapy Treating Chronic Hepatitis B Virus (HBV) Infection
Conditions: Hepatitis B, Chronic
Sex: All
Ages: 18 Years – 60 Years
Healthy volunteers: No
Phase: PHASE2
Enrollment: 91
Sponsor: Brii Biosciences Limited
Location: Investigative Site 61002 Kingswood New South Wales
Summary
This is an open label, randomized, parallel-group study to evaluate the safety and efficacy of combination treatment BRII-835 (VIR-2218) and BRII-179 (VBI-2601) in adult participants with chronic HBV infection
Eligibility Criteria
Inclusion Criteria:
* Male or female aged 18 - 60
* Body mass index ≥ 18 kg/m\^2 and ≤ 32 kg/m\^2
* Chronic HBV infection as defined by a positive serum HBsAg for ≥ 6 months
Exclusion Criteria:
* Any clinically significant chronic or acute medical condition that makes the volunteer unsuitable for participation
* Significant fibrosis or cirrhosis
* History or evidence of drug or alcohol abuse
* History of intolerance to SC or IM injection
* History of chronic liver disease from any cause other than chronic HBV infection
* History of hepatic decompensation
Source: ClinicalTrials.gov (NCT04749368). StuddyBuddy aggregates publicly available trial information.
